ScripTwo RNA technology specialists created by venture capital investor MPM BioImpact and launched with large amounts of money to pursue their ambitious ideas will bring their shared economic interests und
ScripChinese developers of radionuclide-based therapies snapped up sizable fundraising deals in March, backed by venture capital (VC) and private equity (PE) funds, while innovative vaccines and cell/gene